Paula Ofek
Overview
Explore the profile of Paula Ofek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenberg I, Khair F, Merenbakh-Lamin K, Sokol E, Goldberg A, Simkin D, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39888380
Background: Colorectal cancer (CRC) ranks as the fourth most common cause of brain metastasis (BM), with its incidence on the rise. However, the molecular mechanisms driving the formation of these...
2.
Ofek P, Yeini E, Arad G, Danilevsky A, Pozzi S, Luna C, et al.
Int J Cancer
. 2023 May;
153(3):654-668.
PMID: 37141410
Glioblastoma (GB) is the most aggressive neoplasm of the brain. Poor prognosis is mainly attributed to tumor heterogeneity, invasiveness and drug resistance. Only a small fraction of GB patients survives...
3.
Pozzi S, Scomparin A, Ben-Shushan D, Yeini E, Ofek P, Nahmad A, et al.
JCI Insight
. 2022 Aug;
7(17).
PMID: 35980743
Development of resistance to chemo- and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors,...
4.
Krivitsky A, Pozzi S, Yeini E, Israeli Dangoor S, Zur T, Golan S, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959480
Development of chemo-resistance is a major challenge in glioblastoma (GB) treatment. This phenomenon is often driven by increased activation of genes associated with DNA repair, such as the alkyl-removing enzyme...
5.
Pozzi S, Scomparin A, Israeli Dangoor S, Ajamil D, Ofek P, Neufeld L, et al.
Adv Drug Deliv Rev
. 2021 Apr;
175:113760.
PMID: 33838208
The complexity and diversity of the biochemical processes that occur during tumorigenesis and metastasis are frequently over-simplified in the traditional in vitro cell cultures. Two-dimensional cultures limit researchers' experimental observations...
6.
Yeini E, Ofek P, Pozzi S, Albeck N, Ben-Shushan D, Tiram G, et al.
Nat Commun
. 2021 Mar;
12(1):1912.
PMID: 33771989
Glioblastoma (GB) is a highly invasive type of brain cancer exhibiting poor prognosis. As such, its microenvironment plays a crucial role in its progression. Among the brain stromal cells, the...
7.
Yanovich-Arad G, Ofek P, Yeini E, Mardamshina M, Danilevsky A, Shomron N, et al.
Cell Rep
. 2021 Mar;
34(9):108787.
PMID: 33657365
Glioblastoma (GBM) is the most aggressive form of glioma, with poor prognosis exhibited by most patients, and a median survival time of less than 2 years. We assemble a cohort...
8.
Zafir-Lavie I, Sherbo S, Goltsman H, Badinter F, Yeini E, Ofek P, et al.
J Control Release
. 2018 Oct;
291:80-89.
PMID: 30342077
Background: Trastuzumab is a monoclonal antibody which demonstrates efficacy for HER2 positive breast cancer patients. Recently, an increased incidence of brain metastasis in trastuzumab-treated patients has been reported. The reason...
9.
Tiram G, Ferber S, Ofek P, Eldar-Boock A, Ben-Shushan D, Yeini E, et al.
FASEB J
. 2018 Jun;
:fj201701568R.
PMID: 29856660
Glioblastoma is an aggressive and invasive brain malignancy with high mortality rates despite current treatment modalities. In this study, we show that a 7-gene signature, previously found to govern the...
10.
Gibori H, Eliyahu S, Krivitsky A, Ben-Shushan D, Epshtein Y, Tiram G, et al.
Nat Commun
. 2018 Jan;
9(1):16.
PMID: 29295989
The heterogeneity of pancreatic ductal adenocarcinoma (PDAC) suggests that successful treatment might rely on simultaneous targeting of multiple genes, which can be achieved by RNA interference-based therapeutic strategies. Here we...